Abbott Laboratories $ABT Position Boosted by Vontobel Holding Ltd.

Vontobel Holding Ltd. raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 11.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,365,628 shares of the healthcare product maker’s stock after acquiring an additional 637,184 shares during the quarter. Abbott Laboratories makes up 2.8% of Vontobel Holding Ltd.’s investment portfolio, making the stock its 4th largest holding. Vontobel Holding Ltd. owned 0.37% of Abbott Laboratories worth $865,789,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of ABT. Maryland State Retirement & Pension System lifted its holdings in shares of Abbott Laboratories by 4.0% during the 2nd quarter. Maryland State Retirement & Pension System now owns 84,163 shares of the healthcare product maker’s stock valued at $11,447,000 after buying an additional 3,275 shares during the last quarter. Optas LLC lifted its holdings in shares of Abbott Laboratories by 9.3% during the 2nd quarter. Optas LLC now owns 6,623 shares of the healthcare product maker’s stock valued at $901,000 after buying an additional 564 shares during the last quarter. Fluent Financial LLC lifted its holdings in shares of Abbott Laboratories by 43.8% during the 2nd quarter. Fluent Financial LLC now owns 31,940 shares of the healthcare product maker’s stock valued at $4,344,000 after buying an additional 9,723 shares during the last quarter. Clear Creek Financial Management LLC lifted its holdings in shares of Abbott Laboratories by 10.9% during the 2nd quarter. Clear Creek Financial Management LLC now owns 5,009 shares of the healthcare product maker’s stock valued at $681,000 after buying an additional 494 shares during the last quarter. Finally, Narwhal Capital Management lifted its holdings in shares of Abbott Laboratories by 9.2% during the 2nd quarter. Narwhal Capital Management now owns 65,569 shares of the healthcare product maker’s stock valued at $8,918,000 after buying an additional 5,514 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ABT shares. Leerink Partners started coverage on Abbott Laboratories in a report on Monday, June 16th. They set a “market perform” rating and a $143.00 price target for the company. Leerink Partnrs upgraded Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. The Goldman Sachs Group boosted their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Mizuho upped their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Finally, Morgan Stanley upped their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $146.24.

Abbott Laboratories Stock Up 1.1%

Shares of ABT stock opened at $134.45 on Thursday. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The firm has a market cap of $234.00 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. The stock has a 50 day moving average of $132.30 and a 200-day moving average of $131.48. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts’ consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories’s revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.